2nd deadliest cancer
Colorectal cancer is the second deadliest cancer worldwide for both sexes, with over 900,000 annual deaths and 1.9 million annual new cases.7
Overview
Identifying individuals at risk for lower GI disorders and iron deficiency anemia
In the US, 5–12% of non-pregnant women and 1–5% of men have iron deficiency anemia (IDA), while occult bleeding from the GI tract is the leading cause for IDA in men and postmenopausal women.2 Bleeding lesions in the GI tract are identified in about 50% of patients with IDA.3 GI malignancy is also significantly more common in men and postmenopausal women with IDA, with a prevalence of 10–17%.4–6
Early detection
Detecting CRC early is crucial, as the 5-year survival rate for CRC in the US (early stages, both sexes) is 90% for localized stages.8
Screening compliance
In the US, only about 59% of adults aged 45 and older are up to date with colorectal cancer screening, and screening prevalence varies substantially across populations.9
navify® Algorithms, LGI-Flag
LGI-Flag is a software tool that is intended to identify individuals at risk for lower GI disorders that warrant further evaluation.¹
The imperative of early screening
Despite recommendations from the U.S. Preventative Services Task Force (USPSTF) for routine screening beginning at age 45, fewer than one-third (~33%) of colorectal cancers are diagnosed at an early stage in the US10 — partially reflecting suboptimal screening participation.
~33%early stage diagnosis.10
Harnessing data: transforming complete blood count (CBC) data into health insights
There is a need to proactively identify and diagnose GI disorders earlier. Despite significant efforts and evidence to suggest the benefits of being screened for colorectal cancer (CRC), many eligible patients are not being screened for it.11 LGI-Flag uses demographic information (age, sex) and historic CBC test results to flag individuals with CBC patterns that may be associated with an increased risk for lower GI disorders.1
The intended use of LGI-Flag: driving patient insights on GI health
Identify individuals at risk
LGI-Flag is a computational software tool used to identify individuals at risk for lower GI disorders that warrant further evaluation.1
Algorithm parameters
LGI-Flag uses demographic information (age and gender at birth) and historic CBC test results electronically available in clinical data repositories and patients' electronic health records (EHR).1
Indicated target audience
LGI-Flag is indicated for use in individuals of the general population, between 45 and 75 years of age, who are not under active GI surveillance.1
Benefits
Enhance colorectal screening: the key advantages of LGI-Flag
By leveraging LGI-Flag, healthcare providers can enhance patient screening processes, improve detection rates and ultimately drive better health outcomes in the fight against colorectal cancer.1,11
8×more effective
More CRC cases (all stages) detected in the flagged population compared with routine CRC colonoscopy screenings11
76%operational impact
proportion of overdue patients agreed to undergo screening (following personalized outreach)11
70%lower GI findings
in the flagged patients who completed colonoscopy (or screening)11
Integration via navify Algorithm Suite
Experience a single integrated platform designed for healthcare providers and laboratories that simplifies IT complexity while reducing the risk of vulnerabilities. With integrated Roche and partner medical algorithms, we provide a comprehensive solution that streamlines processes and enhances collaboration.
Single interface for customer support
Roche offers centralized customer support for all algorithms in our portfolio to ensure consistency and reliability. We manage issues that arise for all hosted algorithms, streamlining the process and eliminating the need for customers to engage with individual providers.
Security and data privacy
Security and data privacy are central to Roche's operations, founded on a "Security and Privacy by Design" philosophy and ISO/IEC 27001 certification. Our dedicated technical team performs ongoing risk assessments, penetration tests, and network monitoring to minimize IT complexity and vulnerabilities, prioritizing data confidentiality to protect patient information across all partners.
Frequently asked questions
If you don’t find answers to your questions here, we’re happy to provide more information and discuss your needs in detail.
Roche Diagnostics
At Roche Diagnostics, we understand the need to go beyond our products and see the bigger picture, creating a world where product and services come together. Roche Service Solutions refers to our service offering and encompasses our full service portfolio. Our total solution package means we can provide you with the personalised mix of products and services you need. Our digital services enable you to quickly connect with us and help make your life more manageable.
- Method Sheet LGI-Flag 3.1. 2024. Material number 09883843001.
- Clark SF. Iron deficiency anemia. Nutr Clin Pract. 2008 Apr-May;23(2):128–141. DOI:10.1177/0884533608314536.
- Powell N, McNair A. Gastrointestinal evaluation of anemic patients without evidence of iron deficiency. Eur J Gastroenterol Hepatol. 2008;20:1094–1100. DOI:10.1097/MEG.0b013e328304d621.
- Not every digital product is available in all markets. The use of any third-party app is subject to a separate license agreement with the respective third-party app developer. Roche gives no warranties (express or implied) with regard to any third-party app. Third-party apps might not be available in your country. This website and its content may be accessible worldwide, Roche assumes no liability with regard to the access to the information, which may not be compatible with legislations or regulations in force in your country.
- *LGI-Flag is FDA exempt in the US and commercially available in the US only.